ProMIS Neurosciences Inc (PMN.CA) Stock Price, Quote, News and Overview
TSX:PMN - Toronto Stock Exchange - CA74346M4065 - Common Stock - Currency: CAD
PMN.CA Quote, Performance and Key Statistics
TSX:PMN (7/21/2023, 7:00:00 PM)
6
-0.24 (-3.85%)
The current stock price of PMN.CA is 6 CAD. In the past month the price increased by 10.91%. In the past year, price decreased by -22.08%.
PMN.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 261.54M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 188.23M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 185.09M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 121.39M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 89.95M | ||
| ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 82.42M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 78.27M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 25.45 | 76.72M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | 48.5 | 65.22M | ||
| MDCX.CA | MEDICUS PHARMA LTD | N/A | 61.74M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 51.96M |
Related stock screener links
About PMN.CA
Company Profile
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario and currently employs 6 full-time employees. The company went IPO on 2005-09-30. The firm is engaged in the development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The firm operates through a single segment: Canada. The firm's discovery engine comprises two complementary algorithms, ProMIS, and Collective Coordinates. The Company’s complementary algorithms predict and identify novel targets known as Disease Specific Epitopes (DSEs). Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The firm also plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), and schizophrenia. The firm's subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
Company Info
ProMIS Neurosciences Inc
Suite 200, 1920 Yonge Street
TORONTO ONTARIO M4S 3E2 CA
CEO: Elliot Goldstein
Employees: 6
Company Website: https://promisneurosciences.com/
Phone: 14168476898.0
ProMIS Neurosciences Inc / PMN.CA FAQ
What is the stock price of ProMIS Neurosciences Inc today?
The current stock price of PMN.CA is 6 CAD. The price decreased by -3.85% in the last trading session.
What is the ticker symbol for ProMIS Neurosciences Inc stock?
The exchange symbol of ProMIS Neurosciences Inc is PMN and it is listed on the Toronto Stock Exchange exchange.
On which exchange is PMN.CA stock listed?
PMN.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for ProMIS Neurosciences Inc stock?
5 analysts have analysed PMN.CA and the average price target is 26.52 CAD. This implies a price increase of 342% is expected in the next year compared to the current price of 6. Check the ProMIS Neurosciences Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ProMIS Neurosciences Inc worth?
ProMIS Neurosciences Inc (PMN.CA) has a market capitalization of 51.48M CAD. This makes PMN.CA a Micro Cap stock.
How many employees does ProMIS Neurosciences Inc have?
ProMIS Neurosciences Inc (PMN.CA) currently has 6 employees.
What are the support and resistance levels for ProMIS Neurosciences Inc (PMN.CA) stock?
ProMIS Neurosciences Inc (PMN.CA) has a support level at 5.99 and a resistance level at 7.34. Check the full technical report for a detailed analysis of PMN.CA support and resistance levels.
Should I buy ProMIS Neurosciences Inc (PMN.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PMN.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PMN.CA, evaluating the profitability, health, valuation and growth aspects
- ProMIS Neurosciences Inc (PMN.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ProMIS Neurosciences Inc (PMN.CA) Sales and EPS estimates to see what analysts future expectations are.
- ProMIS Neurosciences Inc (PMN.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ProMIS Neurosciences Inc (PMN.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ProMIS Neurosciences Inc (PMN.CA) Stock Chart to make your own analysis
- ProMIS Neurosciences Inc (PMN.CA) Latest news and press-releases to stay up to date.
Does ProMIS Neurosciences Inc (PMN.CA) stock pay dividends?
PMN.CA does not pay a dividend.
What is the Price/Earnings (PE) ratio of ProMIS Neurosciences Inc (PMN.CA)?
ProMIS Neurosciences Inc (PMN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.5).
PMN.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PMN.CA. When comparing the yearly performance of all stocks, PMN.CA is a bad performer in the overall market: 79% of all stocks are doing better.
PMN.CA Financial Highlights
Over the last trailing twelve months PMN.CA reported a non-GAAP Earnings per Share(EPS) of -3.5. The EPS decreased by -203.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PMN.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to PMN.CA. The Buy consensus is the average rating of analysts ratings from 5 analysts.